abstract BACKGROUND AND OBJECTIVE: There are few data on the rate and characterization of medicationrelated visits (MRVs) to the emergency department (ED) in pediatric patients. We sought to evaluate the frequency, severity, preventability, and classification of MRVs to the ED in pediatric patients.
WHAT'S KNOWN ON THIS SUBJECT:
In adults, adverse drug events account for 5% to 25% of all hospital admissions and 12% of emergency department (ED) visits of which 50% to 70% are preventable. There remains a significant gap in our understanding of the magnitude and impact of medication-related ED visits in pediatrics.
WHAT THIS STUDY ADDS:
This study is the largest and most rigorous study performed evaluating the impact of medication-related visits to the ED in pediatrics and provides important information regarding the magnitude of this problem in our health care system. Adverse drug events (ADEs) are unfavorable occurrences related to the use and misuse of medications. 1 It has been estimated that ADEs account for over 17 million emergency department (ED) visits and 8.7 million hospital admissions annually in the United States. 2, 3 A cost-of-illness model estimated that between 1995 and 2000 costs associated with morbidity and mortality secondary to ADEs more than doubled from US$76.6 billion to more than US$177.4 billion and is likely even higher today. 3, 4 In recent years, ADEs have been extensively evaluated in ambulatory care, [5] [6] [7] [8] [9] ED care, and in hospitalized patients. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] Studies have estimated that 5% to 25% of all hospital admissions and up to 12% of ED visits are medication-related, of which 50% to 70% are deemed preventable. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Studies have involved different methodologies and a spectrum of different inclusion criteria, ranging from studies of narrowly defined adverse drug reactions (ADRs) to more broadly defined medication-related events.
The majority of research performed has provided data for medicationrelated hospital visits in adults, but this issue has been poorly studied in pediatric patients. In the majority of studies published to-date, pediatric patients were either excluded or significantly underrepresented among the study population. Those studies that have been performed in pediatric patients have used retrospective design or significantly limited prospective methodologies, which preclude accurate determination of the magnitude of this issue. 16, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] Retrospective evaluation, often conducted by using medical record review or use of administrative databases, has inherent limitation for reporting bias, challenges with event ascertainment, as well as causality and preventability assessment, and has reported much lower event rates compared with prospective studies. 11, 56 Finally, no study has prospectively explored this issue in Canada, so the impact in our own country remains uncertain. The incidence and classifications of medication-related ADEs in pediatrics cannot be expected to be the same as adults due in large part to the agerelated prevalence of disease, as well as the spectrum and scope of medication use. As a result, approaches to identify and prevent ADEs in pediatric patients will also be unique. Thus, there remains a significant knowledge gap in our understanding of the magnitude and impact of medication-related ED visits in pediatric patients.
We sought to evaluate the frequency, severity, preventability, and classification of medication-related visits (MRVs) to the ED of a large tertiary-care hospital and to identify patient, prescriber, drug, or system factors associated with these visits.
METHODS

Setting and Population
This prospective observational study was conducted at IWK Health Centre, a 120-bed pediatric tertiary-care, referral, and trauma center and Dalhousie University-affiliated Canadian teaching hospital in Halifax, Nova Scotia. The ED treats ∼28 000 patients annually and is staffed by physicians board-certified in emergency medicine or pediatrics. The study was coordinated by the Department of Emergency Medicine, IWK Health Centre. Ethics approval was obtained from the IWK Health Centre Research Ethics Board, and all participating patients provided signed informed consent.
All patients presenting to the ED during a 1-year period from November 1, 2011, to October 31, 2012, were eligible for enrollment. The decision to enroll patients over a 1-year period was made a priori based on a sample size projection to achieve a sufficiently narrow 95% confidence interval (CI; +/24%) around the primary outcome estimate to permit robust conclusions. To ensure a representative sample of patients were enrolled, data collection shifts were stratified a priori by day of week and time of day (0100-0859 h, 0900-1659 h, 1700-0059 h). Patients presenting during data collection shifts over the study period were systematically sampled by using time to presentation to ED triage. Using a computerized randomization program, 1 patient was selected from all patients who presented in the 1-hour period before the start of each data collection shift. Once the first patient was randomly selected at time t =0 , subsequent patients were enrolled at a fixed time interval of 20 minutes from the time of presentation of the first patient. In situations where a patient was selected, but deemed ineligible based on exclusion criteria, the next patient presenting after the ineligible patient was selected. Patients selected for enrollment more than once during the study period were entered as discrete visits. Patients were excluded if they were returning to the ED for a scheduled visit (eg, outpatient antibiotics).
Data Collection and Case Definitions
Data were collected by using a personal digital assistant-based electronic data collection form (Pendragon Software Corporation, Libertyville, IL) by 1 residencytrained pharmacist research assistant experienced in the pharmacotherapeutic aspects of pediatric acute care medicine.
Each patient and their family were interviewed to determine chief complaint, history of present illness, past medical history, medication history, and allergy status. Medication history included prescription, overthe-counter, and complementary and alternative medications. Additional information was obtained when necessary from family physicians, specialists, and their community pharmacy. Information from the physical examination conducted by the attending emergency physician or medical trainee, laboratory results, and diagnostic tests were used when necessary. All such assessments and evaluations were at the discretion of the attending emergency physician, and clinical care and laboratory testing was unaltered as a result of this study. Patients were followed until discharge from the ED or, if admitted, until hospital discharge. Patients were contacted by telephone up to 30 days after hospital discharge for the evaluation of progress and outcomes.
Outcome Measures
An ED visit was deemed medicationrelated if the presentation was directly related to the presenting chief complaint and classified into 1 of 8 predefined categories: ADR, drug interaction, improper drug selection, untreated indication, subtherapeutic dosage, supratherapeutic dosage, nonadherence, and drug use without indication (Supplemental Table 5 ). 57 If a medication-related problem was found incidentally but was unrelated to the presenting chief complaint, the visit was not considered medicationrelated.
The Lexi-Pediatric Suite (Lexi-Comp, Inc, Hudson, OH) was used to obtain drug information and perform drug interaction analysis at the point of care. In addition, the attending emergency physician responsible for the care of each patient was asked if they felt that the visit was medication-related, and if so the nature of the medication-related cause. To allow determination of physician/pharmacist agreement, the emergency physician's assessment was made without knowledge of the pharmacist's assessment.
Causality was determined by using both the modified World Health Organization algorithm and the modified Naranjo algorithm. 58, 59 An adverse drug-related event was considered to be present if the World Health Organization algorithm was deemed "certain" or "probable" or the Naranjo algorithm was deemed "definite" or "probable".
Severity was defined as mild (laboratory abnormality or symptom not requiring treatment), moderate (laboratory abnormality or symptom requiring treatment/hospitalization or resulting in nonpermanent disability), severe (life threatening or resulting in permanent disability), or fatal. 30, 35 Medication-related ED visits were defined as preventable if drug treatment, or lack thereof, was inconsistent with current best practice. This included the following: inappropriate drug, dosage, route, or frequency for patient's clinical condition, age, weight, renal function; known drug allergy or previous reaction to drug; known drug interaction; nonadherence; laboratory monitoring not performed; and prescribing, dispensing, or administration errors. 30, 35, [58] [59] [60] [61] Cases in which there was discordance between the pharmacist and emergency physician categorizations were independently adjudicated by 2 external reviewers (1 physician pediatrician and 1 pharmacist) by using explicit criteria and a predefined approach. 9, 30, 43 Standardized case summaries were prepared by the research pharmacist for review by the external reviewers. These case summaries included all relevant history obtained during the index visit and, where applicable, information obtained from 1-month follow-up. Each adjudicator determined the likelihood of the visit being drug-related by using a 6-point Likert scale. If both reviewers rated the visit as 4 (possibly drug-related but more likely due to drug[s]) or higher, it was deemed to be drugrelated. If both reviewers rated the visit as 3 (possibly drug-related but more likely not due to drug[s]) or less, it was not deemed to be drug-related. If there was disagreement in the ratings, the reviewers discussed the case to achieve consensus.
Statistical Analysis
Patient demographics were summarized by using means and SDs or medians and interquartile ranges for continuous data, and frequencies and percentages for categorical data. The primary outcome was reported as a percentage with 95% CI, calculated by using the ClopperPearson (Exact) method. The 95% CIs were calculated similarly for the percentages of patients admitted to hospital with medication-related and non-MRVs. Univariate association between hospital admission and MRVs was calculated by using odds ratios (ORs). comorbidities. Hence, the use of multiple pharmacies variable was not evaluated in the final model. After multivariable adjusted analysis modeling, the following were found to be independently associated with MRVs: age, CTAS, and number of comorbidities (Table 4) .
DISCUSSION
Our findings indicate that adverse medication-related events comprise 8% of pediatric ED visits and 65% are potentially preventable. Hospitalization rates are higher and length of stay is longer for patients presenting with an MRV compared with patients admitted for other reasons. Our prospective design, large sample size, use of causality assessment tools, and independent adjudication committee increase the likelihood that our estimates are precise. In addition, our use of a careful systematic sampling strategy and a priori enrollment stratification increases the generalizability of our findings.
This is the first prospective study performed in Canada, which has explored the impact of ADEs in pediatric patients who result in ED visits. Surprisingly, our results are similar to the rate of medicationrelated ED visits in adults in Canada, recently reported at 12%. 30 Our prospective design and follow-up at 1-month after the index visit allowed for complete medical and medication histories and ensured all information required to accurately classify cases was obtained. Second, we used an experienced clinical pharmacist trained in the recognition and resolution of ADEs in pediatric patients and considered their assessment in combination with an independent emergency physician assessment. Previous work has revealed that the rate of emergency physicians' recognition of adverse drug-related events is ∼50%, thus studies that rely solely on this assessment will underestimate the incidence of drug-related visits. 29 Finally, our use of a comprehensive classification system increases the likelihood that all medication-related causes of ED visits were identified. Our inclusion of medication nonadherence as a medication-related reason for an ED visit is unique, and reflects our belief that this should be included in estimates of the burden of MRVs. McGrady and Hommel 63 recently reported the significant impact of medication nonadherence and the related increased health care use in children and adolescents who have a chronic medical condition.
The classifications, specific drug therapies, and high rate of preventability identified in our study are consistent with previous reports. 30, 44 Although the overall hospitalization rate we found was also consistent with previous reports, the increased admission rate in patients with an MRV was striking. It remains unclear whether this represents association, causation, or a combination of both, but this increased rate of admission and longer length of stay when admitted is also consistent with adult patients. 30 It is possible that because adverse drug-related events often require time and monitored observation for treatment or resolution, hospital admission is more frequently indicated. Specific risk factors for MRVs are inconsistently identified in the literature 56 ; however, we were able to identify age, CTAS, and the number of comorbidities as predictors of MRVs. These 3 factors would suggest that as patients get older and experience more comorbidities, it would result in a greater likelihood of medication exposure and as a result would predict a greater chance of experiencing an ADE, which would result in an ED visit. Our study has limitations. First, although our trained research pharmacist used a standardized approach, bias may have occurred in the determination of an MRV. We attempted to minimize this through the use of an independent adjudication process. Second, although a standardized approach was used in the formulation of adjudication case summaries, it is conceivable bias may also have been introduced at this stage. In addition to the case summaries, adjudicators were provided with all relevant medical records and made their assessments without the knowledge of the pharmacist or emergency physician determinations. Third, the increased attention to the subject of MRVs resulting from this study may have heightened emergency physicians' awareness of medication-related issues and introduced a Hawthorne effect. Fourth, inherent in working with a pediatric patient population, we had to rely on family and other sources to ascertain much of the history. Natural questions better answered by the patient could simply not be obtained for this patient group. Finally, given the study location, our results are not necessarily generalizable to community or rural hospitals or hospitals that care for a mix of both adult and pediatric patients. 
CONCLUSIONS
